How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

 
• By Eliza Slawther
  
Antibody Drug Conjugate
Debiopharm is interested in licensing Antibody Drug Conjugate drugs for cancer • Source: Shutterstock
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Global Vision

More from In Vivo